NCT05084430View on ClinicalTrials.gov

Study of Pembrolizumab and M032 (NSC 733972)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2028

Conditions
Glioblastoma MultiformeAnaplastic AstrocytomaGliosarcoma
Interventions
DRUG

M032

Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.

DRUG

Pembrolizumab

Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.

Trial Locations (1)

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER